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Abstract  
Background: In a phase III trial, the RTS,S/AS01 malaria vaccine produced lower anti-
circumsporozoite (CS) antibody titres when co-administered with Expanded Programme on 
Immunisation (EPI) vaccines (0,1,2-month schedule) at 6-12 weeks compared to 5-17 months at 
first vaccination. Alternative infant immunisation schedules within the EPI were investigated.  
Methods: This phase II, open, single site (Blantyre, Malawi) trial was conducted in infants aged 
1-7 days. Subjects were equally randomised across seven groups to receive three doses of 
RTS,S/AS01E at time points that included ≤7 days, 6, 10, 14, 26 weeks, and 9 months. All 
RTS,S/AS01E groups plus a control group (without RTS,S/AS01E) received BCG+OPV at ≤7 
days, DTPwHepB/Hib+OPV at 6,10,14 weeks and measles vaccine at 9 months; one 
RTS,S/AS01E group and the control additionally received hepatitis B vaccination at ≤7 days. 
Serum anti-CS antibody geometric mean concentration (GMC; ELISA) and safety were assessed 
up to age 18 months. 
Results: Of the 480 infants enrolled, 391 completed the study. No causally related serious 
adverse event was reported. A higher frequency of fever within 7 days of RTS,S/AS01E 
vaccination compared to control was observed. Compared to the standard 6,10,14 week schedule, 
anti-CS antibody GMC ratios post-Dose 3 were significantly higher in the 10,14,26 week group 
only (ratio 1.80; 95%CI:1.24, 2.60); RTS,S/AS01E vaccination at ≤7 days, 10,14 weeks produced 
significantly lower anti-CS GMCs (ratio 0.59; 95%CI:0.38, 0.92). 
Conclusions: Initiation of RTS,S/AS01E vaccination above six weeks of age tended to improve 
anti-CS antibody responses. Neonatal vaccination was well tolerated, but produced a 
comparatively lower immune response. 
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INTRODUCTION 
Malaria causes devastating morbidity and mortality, with an estimated 214 million malaria cases 
and 438,000 malaria deaths occurring worldwide in 2015.
1
 Malaria mortality occurs 
predominantly in children, with an estimated 306,000 deaths in children younger than five years 
of age each year, of which 95% occur in Africa. 
The development of efficacious malaria vaccines has been identified as a key component of a 
sustainable malaria control program with consequent benefits for health and the economy.
2
 GSK 
Vaccines’ pre-erythrocytic Plasmodium falciparum malaria vaccine, RTS,S/AS01E, consists of 
sequences of the circumsporozoite (CS) protein fused to hepatitis B surface antigen (HBsAg) 
adjuvanted with AS01 (liposome formulation with MPL and QS-21 immunostimulants).
3
  
The Expanded Programme on Immunisation (EPI) is an established program that uses 
immunization regimens aimed at maximizing immunization coverage in order to address disease 
burden early in life. 
During phase II development, lower anti-CS antibody titers were produced when an earlier 
formulation of the vaccine (RTS,S/AS02) as well as the RTS,S/AS01E formulation were co-
administered with EPI vaccines on a 0, 1, 2-month schedule to infants aged 6-12 weeks at first 
vaccination, compared to children aged 1-4 years
4-8
; this difference in immunogenicity did not 
appear to result in a difference in protective efficacy. Although an immature immune system 
and/or an inhibitory effect of maternally derived anti-CS antibodies may have played a role, 
interference of co-administered routine EPI vaccines may also have contributed to the lower 
immunogenicity observed in young infants.
9
 
The current study was designed to investigate alternative vaccination schedules in order to 
improve anti-CS immune responses of RTS,S/AS01E in infants when integrated within an EPI 
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regimen in Blantyre, Malawi. Although no correlate of protection has been established, a link 
between higher anti-CS titers and decreased risk of infection has been shown in some trials.
4,6
 
The exploratory schedules comprised administration of three doses of RTS,S/AS01E between 
birth (neonatal dose) and nine months of age, using different existing contacts with the health 
service. In previous trials with GSK Vaccines’ hepatitis B vaccine, it was observed that 
increasing the interval between the second and third dose enhances humoral response.
10,11
 In this 
study, administration of the third dose of RTS,S/AS01E at 26 weeks of age was investigated to 
assess if increased spacing of RTS,S/AS01E doses improves anti-CS antibody responses.  
Starting hepatitis B immunization at birth or in the neonatal period, as recommended by WHO,
12
 
is desirable to control mother to infant transmission of hepatitis B infection and the subsequent 
development of chronic carriage. Furthermore, previous phase II trials indicated that prior 
hepatitis B vaccination may ‘prime’ for anti-CS antibody response.13,14 Thus, a schedule 
including a neonatal dose of a hepatitis B vaccine (Engerix-B*) was investigated. 
Potential inhibition of RTS,S/AS01E specific immune responses following co-administration 
with DTPw-HepB/Hib was evaluated by the inclusion of schedules in which doses of 
RTS,S/AS01E were not co-administered with DTPw-HepB/Hib (Tritanrix HepB/Hib*). These 
schedules also investigated any effect on anti-CS antibody response of age at first dose of 
RTS,S/AS01E. 
Although there is currently no scheduled visit at six months of age in the EPI, at this time point 
parents of children in Africa are requested to bring their child to their local health facility for 
administration of Vitamin A. An exploratory vaccination schedule within existing EPI visits, but 
outside the EPI DTPw-HepB/Hib vaccination schedule, was also investigated given the 
substantial number of antigens currently administered at these time points and possible future 
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increase in co-administered antigens. In this schedule, the first dose of RTS,S/AS01E was co-
administered with the 3
rd
 dose of DTPw-HepB/Hib, the second dose without co-administration 
but coinciding with a Vitamin A EPI visit and the third dose in co-administration with the 
measles vaccine (Rouvax*).  
The primary aims of the study were to compare CS antigen immunogenicity of RTS,S/AS01E 
between exploratory schedules and the reference schedule at 6, 10, 14 weeks of age, and to 
evaluate safety over an 18 month period. 
*Engerix-B, Tritanrix and Hiberix are trademarks of the GSK group of companies. Rouvax is a 
trademark of Sanofi Pasteur. 
MATERIALS AND METHODS 
A summary of the protocol is available at www.gsk-clinicalstudyregister.com (GSK study 
111315). 
Ethics  
The study was registered with the Pharmacy, Medicines and Poisons Board, Malawi and at 
ClinicalTrials.gov (ClinicalTrials.gov number: NCT01231503). Approval was obtained from the 
National Health Sciences Research Committee, Malawi, the College of Medicine Research 
Ethics Committee, University of Malawi, and the Research Ethics Sub-committee for Physical 
Interventions, University of Liverpool, UK. The trial was conducted in accordance with the 
provisions of the International Conference on Harmonisation and Good Clinical Practice 
guidelines.  
Recruitment of study subjects 
Prior to study start, activities were carried out to raise awareness amongst health professionals in 
Blantyre district, as well as at different levels of the community. 
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Pregnant women who were interested in participating in the study were identified at the antenatal 
clinic at the Bangwe Health Centre, Blantyre, Malawi. Potential recruits were required to be 
resident in the Bangwe study clinic catchment area for the foreseeable future, a minimum age of 
18 years at the time of delivery, in the third trimester of pregnancy (27-42 weeks) and to provide 
informed consent for antenatal screening for hepatitis B and HIV infection. Written informed 
consent for subject participation was requested from mothers antenatally, as ideally cord blood 
was taken for screening purposes. If consent was given >7 days prior to procedures being carried 
out on the child, a brief re-consenting process was performed. 
Only infants whose mothers were negative for carriage of the hepatitis B virus and HIV infection 
were eligible to be screened for the trial. Eligibility criteria included male or female infants aged 
between one and seven days (inclusive), born at full term (gestation period between 37 and 42 
weeks) confirmed by Dubowitz score,
15
 and with a minimum weight of 2.5 kg (see 
Supplementary Appendix, Section 1, http://links.lww.com/INF/C993). Subjects had to be healthy 
as determined by physical examination, medical history records and laboratory screening tests of 
hematology and renal and hepatic function. For participation in the study, no previous 
vaccinations with diphtheria, tetanus, pertussis (whole-cell or acellular), Haemophilus influenzae 
type b, hepatitis B, Bacillus Calmette-Guérin (BCG) tuberculosis, measles or oral polio vaccines 
were allowed. 
Study design 
The study was a phase II, open, randomized, controlled trial with eight groups. All groups 
received standard EPI vaccines. Seven groups additionally received RTS,S/AS01E as a 3-dose 
schedule with or without neonatal hepatitis B vaccine. The control group additionally received a 
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neonatal dose of hepatitis B vaccine (Fig. 1). The study duration was approximately 18 months 
per child.  
Study vaccines, vaccination, randomization 
RTS,S/AS01 is manufactured by GSK Vaccines (Rixensart, Belgium). Each 0.5 mL 
RTS,S/AS01 dose as tested in this study contained RTS,S (25 µg) and AS01E, an Adjuvant 
System containing 25 µg MPL and 25 µg QS-21 (Quillaja saponaria Molina, fraction 21) 
(Licensed by GSK from Antigenics LLC, a wholly owned subsidiary of Agenus Inc., a 
Delaware, USA corporation).
3
 RTS,S/AS01 was administered intramuscularly in the left antero-
lateral thigh.  
EPI vaccines comprised a diphtheria, tetanus, whole-cell pertussis, hepatitis B and Haemophilus 
influenzae type b pentavalent vaccine (Tritanrix HepB/Hib, GSK Vaccines), an oral poliovirus 
vaccine containing serotypes 1, 2 and 3 (Polio Sabin*, GSK Vaccines), a hepatitis B vaccine 
(HepB; Engerix-B, GSK Vaccines), a BCG vaccine (Statens Serum Institute) and an attenuated 
measles vaccine (Rouvax, Sanofi Pasteur). Details for the EPI vaccines and administration are 
provided in Supplementary Appendix, Section 2, http://links.lww.com/INF/C993. 
Treatment allocation was performed at the investigator site using a standard Statistical Analysis 
System (SAS) programmed randomization list generated at GSK Vaccines, Belgium. 
Randomization was not stratified, but ensured an equal number distribution of subjects across 
treatment groups. The sample size of this descriptive phase II trial was powered to detect at least 
a 2-fold difference in GMT between any two groups. 
*Polio Sabin is a trademark of the GSK group of companies. AC
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Immunogenicity assessments 
Immunology assessments are described in detail in Supplementary Appendix Section 3, 
http://links.lww.com/INF/C993. Briefly, anti-CS repeat region IgG antibodies were measured by 
standard ELISA methodology using plate-adsorbed R32LR antigen [NVDP(NANP)15]2LR, as 
previously described.
16
 Antibodies against HBsAg were measured by chemiluminometric 
immunoassay (as measured by the Siemens Centaur XP CLIA). 
Safety assessments  
As this was the first trial of the RTS,S/AS01E candidate malaria vaccine in neonates, a rigorous 
safety monitoring plan was put in place (see Supplementary Appendix, Section 4, 
http://links.lww.com/INF/C993). The study was overseen by an Independent Data Monitoring 
Committee (IDMC) operating under a charter and assisted by two Local Safety Monitors.  
The local injection site and general solicited adverse events (AEs) were monitored over 7 days 
after each vaccination (Days 0-6) and were graded as mild, moderate or severe (Grade 1, 2, 3, 
respectively). All other AEs (unsolicited) were recorded over a 30-day (Days 0-29) period after 
each vaccination. Serious adverse events (SAEs) were captured throughout the study. All 
injection site AEs were considered causally related to vaccination; the causality of all other AEs 
was assessed by the investigator. Hematologic and biochemical tests for safety assessment were 
conducted at various time points during the study.  
At the time of protocol development, two SAEs of febrile seizure within 7 days of vaccination in 
two previous phase II trials, were considered to be causally related to vaccination with 
RTS,S/AS01E.
8,14
 In the large phase III trial,
9,17,18
 an imbalance of meningitis cases of any 
etiology (i.e. including cases with and without confirmed etiology) was observed in children 5-
17 months of age at first dose. Consequently, any febrile seizure occurring within 30 days of 
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vaccination and any case of meningitis occurring during the study were to be recorded as SAEs. 
See Supplementary Appendix, Sections 4 and 5.2, http://links.lww.com/INF/C993 for additional 
details on safety assessments, including assessment of AEs of specific interest. 
Statistical analysis  
All analyses were conducted according to a pre-defined analysis plan. The co-primary endpoints 
of the study were: anti-CS antibody concentrations at 1 month post-Dose 3 of RTS,S/AS01E and 
occurrence of SAEs from study start until Month 10. A second analysis included occurrence of 
SAEs from study start until study end (Month 18; tertiary objective). 
The Total Vaccinated Cohort (TVC) included all subjects who were randomized and received a 
dose of BCG vaccine. All safety analyses were performed on the TVC population. The 
According To Protocol (ATP) cohort for immunogenicity included all subjects in the TVC who 
received all vaccinations according to protocol procedures within specified intervals and did not 
take any immune modifying medication or have blood transfusions. 
Seropositivity rates for CS (≥0.5 EU/mL), pertussis (≥15 EL.U/mL) and measles 
(≥150 mIU/mL) and seroprotective rates for HBs (≥10 mIU/mL), diphtheria (≥0.1 IU/mL), PRP 
(purified capsular polyoside - polyribosylribitol phosphate - of Haemophilus influenzae type b) 
(≥0.15 µg/mL), polio (≥8 ED50 [endpoint dilution 50%]) and tetanus (≥0.1 IU/mL), together 
with geometric mean concentrations (GMCs)/titers (GMTs) plus exact 95% confidence intervals 
(CI) were evaluated. GMC ratios relative to the 6, 10, 14 week regimen were assessed. All safety 
analyses were performed by group and pooled neonatal groups in which safety was evaluated 
after neonatal Dose 1 (pooled RTS,S: ≤7 days, 10, 14 weeks and ≤7 days, 10, 26 weeks groups; 
pooled HepB: ≤7 days HepB, 6, 10, 26 weeks and control groups). Analyses of safety following 
three doses of RTS,S/AS01E or DTPw-HepB/Hib alone enabled comparison of equal follow up 
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and number of vaccination visits; age at vaccination and number of doses of RTS,S/AS01E co-
administered with DTPw-HepB/Hib differed. Statistical analyses were conducted using SAS 
version 8 (SAS, Cary, NC, USA) and further details are available in Supplementary Appendix, 
Section 5, http://links.lww.com/INF/C993. 
RESULTS 
Study population 
Of the 480 subjects enrolled at birth, 479 were vaccinated, of whom 391 completed the study. 
The main reasons for withdrawal of the 88 subjects were consent withdrawal and migration/lost 
to follow up (Fig. 2). 
All infants were less than 7 days old at the time of neonatal vaccination with BCG (Screening 
visit). An equal proportion of males and females were enrolled (Supplementary Table 1, 
http://links.lww.com/INF/C993). 
Immunogenicity outcomes 
Post-Dose 3 anti-CS GMCs ranged from 128.2 EU/mL to 392.6 EU/mL across all RTS,S/AS01E 
co-administration schedules (Fig. 3). Anti-CS antibody responses persisted to Month 18 in all 
seven RTS,S/AS01E schedules. 
In subjects vaccinated at 6, 10, 14 weeks of age (i.e. the reference group for evaluation of anti-
CS antibody response) the anti-CS antibody GMC post-Dose 3 was 218.3 EU/mL (95% CI: 160, 
298). A higher anti-CS antibody GMC ratio was  observed post-Dose 3 only in the two groups 
where vaccination with RTS,S/AS01E started after 6 weeks of age, i.e. in the 10, 14, 26 week and 
14, 26 week, 9 month groups, with a statistically significant increase in the 10, 14, 26 week 
schedule only (GMC ratio 1.80; 95% CI: 1.24, 2.60) as compared to the reference schedule (6, 
10, 14 weeks in co-administration with DTPw-HepB/Hib + OPV) (Table 1). 
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Relatively lower anti-CS responses post-Dose 3 were observed in groups receiving the first dose 
of RTS,S/AS01E within 7 days of birth (≤7 days, 10, 14 week group: 128 EU/mL [95% CI: 92, 
178]; ≤7 days, 10, 26 week group: 137 EU/mL [95% CI: 93, 201]), which was statistically 
significant compared to vaccination at 6, 10, 14 weeks of age in the ≤7 days, 10, 14 week group 
(GMC ratio 0.59; 95% CI: 0.38, 0.92). 
Increasing the interval from 1 month to 3 months between Doses 2 and 3 of RTS,S/AS01E did 
not increase anti-CS response (post-Dose 3 anti-CS antibody GMC ratios: ≤7 days, 10, 14 week 
group vs ≤7 days, 10, 26 week group, 0.94 [95% CI: 0.57, 1.54]; 6, 10, 14 week group vs 6, 10, 
26 week group, 1.39 [95% CI: 0.82, 2.38]).  
A neonatal dose of a hepatitis B vaccine did not increase the anti-CS response (post-Dose 3 anti-
CS antibody GMT ratio: 6, 10, 26 week group vs HepB ≤7 days, 6, 10, 26 week group, 0.92 
[95% CI: 0.51, 1.66]). 
One month after a single dose of measles vaccine at Month 9, there was a trend for lower anti-
measles antibody GMCs with RTS,S/AS01E co-administration (14, 26 week, 9 month group), 
though similar seropositivity rates were observed with or without (control group) co-
administration of RTS,S/AS01E (14, 26 week, 9 month group: 92.3% [95% CI: 81.5, 97.9] 
seropositive, GMC 1018 mIU/mL [95% CI: 752, 1377]; control group: 89.1% [95% CI: 76.4, 
96.4] seropositive, GMC 1431 mIU/mL [95% CI: 997, 2053]). Antibody responses to pertussis, 
diphtheria, PRP, tetanus, OPV and measles antigens are summarized in Supplementary Table 10, 
http://links.lww.com/INF/C993.  
All RTS,S/AS01E regimens induced high anti-HBs antibody responses (Supplementary Figure 1, 
http://links.lww.com/INF/C993); 100% of subjects were seroprotected for anti-HBs antibodies at 
all time points assessed up to Month 18. In the control group receiving a hepatitis B vaccine as a 
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neonatal dose followed by three doses of DTPw-HepB/Hib at 6, 10, 14 weeks of age (current 
standard of care), 100%, 97.1% and 88.1% of subjects were seroprotected for anti-HBs 
antibodies at Month 5, Month 10 and Month 18, respectively. 
Safety outcomes 
Serious AEs  
The proportion of subjects who experienced at least one SAE from study start until Month 10 
(primary safety endpoint) ranged across study groups from 5.0% to 16.7% (Table 2; 
Supplementary Table 3, http://links.lww.com/INF/C993). Two subjects (1.7%) reported SAEs 
following a neonatal dose of RTS,S/AS01E and 3 subjects (2.5%) following a neonatal dose of a 
hepatitis B vaccine. Over 18 months’ surveillance, no safety concern was apparent across the 
different groups (Supplementary Table 4, http://links.lww.com/INF/C993). Three fatal SAEs 
were reported: respiratory distress (6, 10, 14 week group), acute respiratory distress syndrome 
(10, 14, 26 week group) and drowning (6, 10, 26 week group). No SAE was considered by the 
investigator to be causally related to vaccination. 
Unsolicited AEs 
The unsolicited AE profile was generally similar across groups (Supplementary Table 5, 
http://links.lww.com/INF/C993). Grade 3 (severe) unsolicited AEs were reported in 0.0% to 
5.0% of subjects in any RTS,S/AS01E group and in 0.0% of subjects in the control group 
(Supplementary Table 6, http://links.lww.com/INF/C993). Two subjects reported unsolicited 
AEs considered to be causally related to vaccination: injection site swelling (6, 10, 26 week 
group) and gastroenteritis (≤7 day, 10, 26 week group). No subject was withdrawn due to an AE 
post RTS,S/AS01E vaccination. Unsolicited AEs within 30 days post-neonatal vaccination were 
reported in 21.8% and 27.5% of infants receiving RTS,S/AS01E or a hepatitis B vaccine, 
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respectively (Supplementary Table 7, http://links.lww.com/INF/C993); none was considered to 
be causally related to vaccination.  
Meningitis occurred in two infants: neonatal meningitis with no etiologic diagnosis in one 
subject in the ≤7 days, 10, 14 week group which was reported 7 days post-Dose 1 of 
RTS,S/AS01E and pneumococcal meningitis in one subject in the 10, 14, 26 week group reported 
8 days post-Dose 1 of DTPw-HepB/Hib + OPV administered at 6 weeks of age without 
RTS,S/AS01E co-administration. Neither event was considered to be related to vaccination and 
both resolved without sequelae. No case of generalized convulsive seizure within 30 days of 
vaccination was reported in any study group.  
Reactogenicity 
The incidence of solicited local AEs (pain, redness, swelling) and solicited general AEs of 
drowsiness, irritability and loss of appetite was generally similar in the RTS,S/AS01E groups and 
the control group and similar following a neonatal dose of RTS,S/AS01E or a hepatitis B vaccine 
(Supplementary Tables 8, 9, http://links.lww.com/INF/C993; Supplementary Figures 2, 3, 
http://links.lww.com/INF/C993). There was a higher frequency of fever (temperature ≥37.5°C) 
in most of the RTS,S/AS01E groups compared to the control group and following a neonatal dose 
of RTS,S/AS01E compared to a neonatal dose of a hepatitis B vaccine (Fig. 4, Supplementary 
Table 9, http://links.lww.com/INF/C993). Grade 3 fever (temperature >39.0°C) was reported in 
three subjects after Dose 1 of RTS,S/AS01E and in a further two subjects after Dose 3 of 
RTS,S/AS01E. No Grade 3 fever was reported after a neonatal dose of RTS,S/AS01E. No Grade 
3 fever was reported in the control group. 
‘ 
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Clinical laboratory evaluations 
No Grade 4 abnormalities (potentially life-threatening) in biochemistry values were reported. 
Low hemoglobin and/or platelet values were graded 4 in five subjects in the RTS,S/AS01E 
groups, two following a neonatal dose of RTS,S/AS01E, and one subject in the control group, 
following a neonatal dose of a hepatitis B vaccine; none of the subjects had any relevant general 
medical history nor associated AE and none of the Grade 4 values was considered related to 
vaccination by the Investigator or by the IDMC. These subjects all continued in the trial and 
completed the study procedures in good health. 
DISCUSSION 
This study has shown that superior anti-CS antibody levels were achieved following 
administration of the first dose of the RTS,S/AS01E malaria vaccine to Malawian infants at 10 
weeks of age on a 10, 14, 26 week schedule, compared to at 6 weeks of age on a 6, 10, 14 week 
schedule. This first study to include a neonatal dose of RTS,S/AS01E, demonstrated an 
acceptable safety profile, but a reduced immune response. 
In the pivotal phase III clinical trial of RTS,S/AS01E, approximately 15,000 infants aged 6-12 
weeks and children aged 5-17 months at first vaccination were enrolled across 11 sub-Saharan 
African sites. Administration of three doses of RTS,S/AS01E one month apart resulted in 
protection against clinical malaria of 45% in the 5-17 month age group and 27% in the 6-12 
week age group during 18 months’ follow up after the third dose.9 Anti-CS antibody titres were 
lower in the younger age category in which the mean age at first vaccination with RTS,S/AS01E 
was 7.1 (standard deviation 1.4) weeks compared to 10.6 (standard deviation 3.8) months in the 
older age group.
17
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In the current study, all seven RTS,S/AS01E co-administration schedules yielded anti-CS 
antibody responses, which persisted to Month 18.  
Of note, infants who received RTS,S/AS01E above six weeks of age as opposed to at 6, 10 and 
14 weeks of age had an increase in post-Dose 3 anti-CS antibody GMC, which was statistically 
significant for the 10, 14 and 26 week group.  
Lower anti-CS antibody responses were observed in infants receiving their first dose within a 
week of birth (≤7 days, 10, 14 week and ≤7 days, 10, 26 week schedules), with significantly 
lower titers compared to vaccination at 6, 10 and 14 weeks of age for the ≤7 days, 10, 14 week 
group. In the neonatal vaccine schedules, RTS,S/AS01E was co-administered with only one or 
two doses of EPI vaccines compared to all three doses in the 6, 10, 14 week reference schedule, 
possibly indicating that the maturity of the immune system and/or inhibition due to maternally 
acquired antibodies, rather than an inhibitory co-administration response, could be implicated in 
the observed reduction in anti-CS titers compared to older children.
18
 
Consistent with previous findings, there was no indication that increasing the spacing of the third 
dose of RTS,S/AS01E was associated with higher anti-CS antibody responses,
19
 contrary to 
responses to hepatitis B vaccination in which improved anti-HBs antibody responses have been 
observed using this approach.
10,11
 Earlier studies reported enhanced anti-CS antibody responses 
post RTS,S/AS01E vaccination in subjects who had previously received a dose of hepatitis B 
vaccine as part of EPI prior to study participation.
13,14
 However, in this study anti-CS responses 
were similar when RTS,S/AS01E was administered at 6, 10 and 26 weeks of age, with or without 
neonatal hepatitis B vaccination. 
An exploratory schedule of RTS,S/AS01E outside the EPI DTPw-HepB/Hib vaccination visits, in 
which the first dose was given at 14 weeks of age in co-administration with the third dose of 
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DTPw-HepB/Hib, the second dose at 6 months of age without co-administration but correlating 
with a Vitamin A EPI visit and the third dose at 9 months of age in co-administration with 
measles vaccination, produced high post-Dose 3 anti-CS antibody responses. Although GMCs 
for anti-measles antibody responses tended to be lower in the RTS,S/AS01E co-administration 
group, seropositivity rates were similar with or without RTS,S/AS01E co-administration. Non-
inferiority of anti-measles seroconversion rates has previously been demonstrated for 
RTS,S/AS01E co-administered with measles vaccine compared with measles vaccine given 
alone.
7
 
High anti-HBs antibody titers following RTS,S/AS01E vaccination compared to standard 
hepatitis B containing EPI vaccines were demonstrated for all seven schedules investigated. All 
subjects receiving three doses of RTS,S/AS01E maintained seroprotective levels of anti-HBs 
antibodies over an 18 month duration. In contrast, anti-HBs seroprotection rates in subjects 
receiving a hepatitis B vaccine as a neonatal dose followed by three doses of DTPw-HepB/Hib 
decreased to 88.1% at Month 18.  
RTS,S/AS01E was well tolerated in infants aged 1-7 days at first vaccination, with no SAE 
assessed as being causally related to vaccination. No subject was withdrawn due to an AE post 
RTS,S/AS01E vaccination over the 18 month surveillance period of the study. In this first study 
of neonatal administration of RTS,S/AS01E, the reactogenicity profile of a neonatal dose was 
comparable to that following vaccination of infants six weeks of age or older. As has been 
previously observed with RTS,S/AS01E vaccination, transient mild to moderate fever occurs 
more frequently in RTS,S/AS01E groups than comparator groups.
18,20
 
Since initiation of enrolment to the current study in January 2011, the candidate RTS,S/AS01E 
malaria vaccine has progressed to regulatory review. In 2015 the European Medicines Agency 
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adopted a positive scientific opinion on the benefit-risk balance of RTS,S/AS01E.
21,22
 
Subsequently, the WHO recommended pilot implementation of RTS,S/AS01E vaccine in 
children as a four dose schedule in sub-Saharan Africa, covering moderate-to-high transmission 
settings; the first dose to be administered as soon as possible after reaching 5 months of age, the 
subsequent two doses after a minimal interval of 4 weeks and a fourth dose at 15 to 18 months 
after the third dose.
23
 However, depending on malaria transmission, a substantial amount of 
malaria episodes can occur before the age of 5 months and an effective malaria vaccine that 
could be given together with some of the well-established EPI vaccination visits would be of 
added value to malaria control efforts. 
The results of the present study indicate that first administration of RTS,S/AS01E in co-
administration with EPI vaccines at a slightly older age improves anti-CS immune responses. We 
note that this was a phase II study, with a small sample size, and as a consequence results are 
descriptive rather than confirmatory since we have relatively low power to differentiate 
statistically between the groups for immunology and safety endpoints. Although no correlate of 
protection has been established, a link between higher anti-CS titers and decreased risk of 
infection has been shown in the challenge model and Active Detection of Infection trials,
4-6,24-28
 
but not in Active or Passive Case Detection trials.
5,8
 The trial did not have an efficacy endpoint 
and in the absence of a correlate of protection, the potential effect of the assessed schedules on 
malaria reduction could not be measured. Nevertheless, this study shows the potential to 
optimize immune responses to RTS,S/AS01E by changing the immunization schedules, thereby 
potentially allowing for flexibility and alignment with health care delivery programs. More 
evidence is required on the feasibility of co-administration, and potential benefit in terms of 
efficacy, of RTS,S/AS01E vaccination at a later age within the EPI schedule. 
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Figure legends 
Figure 1. Study design overview: study groups, vaccinations 
RTS,S = RTS,S/AS01E 
HepB = Hepatitis B vaccine (Engerix-B) 
≤7D, 10, 14W group = RTS,S/AS01E at ≤7 days, 10 and 14 weeks 
≤7D, 10, 26W group = RTS,S/AS01E at ≤7 days, 10 and 26 weeks 
6, 10, 14W group = RTS,S/AS01E at 6, 10 and 14 weeks 
6, 10, 26W group = RTS,S/AS01E at 6, 10 and 26 weeks 
≤7D HepB, 6, 10, 26W = HepB vaccine at ≤7 days, and RTS,S/AS01E at 6, 10 and 26 week s 
10, 14, 26W group = RTS,S/AS01E at 10, 14 and 26 weeks 
14, 26W, 9M = RTS,S/AS01E at 14, 26 weeks and 9 months 
Control = HepB vaccine at ≤7 days  
BCG = Bacillus Calmette-Guérin (BCG) (tuberculosis) vaccine (Statens Serum Institute and 
Biovac Institute Commercial BCG) 
OPV = oral poliovirus vaccine (Polio Sabin, GSK Vaccines) 
DTPwHepB/Hib = diphtheria, tetanus, whole-cell pertussis, hepatitis B and Haemophilus 
influenzae type b vaccine (Tritanrix HepB/Hib, GSK Vaccines) 
Measles vaccine = attenuated measles vaccine (Rouvax, Sanofi) 
Figure 2. CONSORT diagram for study participants  
≤7D, 10, 14W = RTS,S/AS01E at ≤7 days, 10 and 14 weeks 
≤7D, 10, 26W = RTS,S/AS01E at ≤7 days, 10 and 26 weeks 
6, 10, 14W = RTS,S/AS01E at 6, 10 and 14 weeks 
6, 10, 26W = RTS,S/AS01E at 6, 10 and 26 weeks 
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≤7D HepB, 6, 10, 26W = HepB vaccine at ≤7 days, and RTS,S/AS01E at 6, 10 and 26 weeks 
10, 14, 26W = RTS,S/AS01E at 10, 14 and 26 weeks 
14, 26W, 9M = RTS,S/AS01E at 14, 26 weeks and 9 months 
Control = HepB vaccine at ≤7 days 
Enrolled = number of subjects who were enrolled in the study 
Completed = number of subjects who completed last study visit 
Withdrawn = number of subjects who did not come back for the last visit 
CW = consent withdrawal (not due to an AE) or parent withdrew child 
AE = adverse event 
LFU = lost to follow up (subjects with complete/incomplete vaccination course) or migrated 
SAE = serious adverse event 
PV = protocol violation 
Figure 3. GMCs for anti-CS antibody concentration at each time point by group (ATP cohort for 
immunogenicity) 
6, 10, 14W = RTS,S/AS01E at 6, 10 and 14 weeks 
≤7D, 10, 14W = RTS,S/AS01E at ≤7 days, 10 and 14 weeks 
≤7D, 10, 26W = RTS,S/AS01E at ≤7 days, 10 and 26 weeks 
6, 10, 26W = RTS,S/AS01E at 6, 10 and 26 weeks 
≤7D HepB, 6, 10, 26W = HepB vaccine at ≤7 days, and RTS,S/AS01E at 6, 10 and 26 weeks 
10, 14, 26W = RTS,S/AS01E at 10, 14 and 26 weeks 
14, 26W, 9M = RTS,S/AS01E at 14, 26 weeks and 9 months 
Control = HepB vaccine at ≤7 days 
GMC = geometric mean concentration 
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Figure 4. Bar graph of solicited local and general symptoms reported during the 7-day (Days 0-
6) post vaccination period following neonatal dose of RTS,S/AS01E or a hepatitis B vaccine; 
pooled neonatal groups (Total Vaccinated Cohort) 
 
RTS,S = Pooled neonatal RTS,S groups (≤7 days, 10, 14 weeks and ≤7 days, 10, 26 weeks 
groups) 
HepB = Pooled neonatal HepB vaccine groups (HepB vaccine at ≤7 days, RTS,S/AS01E at 6, 10 
and 26 weeks and Control [HepB vaccine at ≤7 days] groups) 
*Combined local reactogenicity of RTS,S/AS01E or HepB vaccine and BCG vaccination 
**Combined general reactogenicity of RTS,S/AS01E or HepB vaccine and BCG vaccination 
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Table 1 Anti-CS antibody GMC ratio post-Dose 3 in each study group compared to 6, 10, 14 week group 
(ATP cohort for immunogenicity)   
RTS,S/AS01 group* N Anti-CS antibody GMC Anti-CS antibody GMC ratio vs 6, 10, 14W 
  GMC 95% CI GMC ratio 95% CI** 
6, 10, 14W 45 218.3 160.1 297.6 -   
6, 10, 26W 46 156.5 100.4 244.0 0.72 0.42 1.22 
≤7 days, 10, 14W 47 128.2 92.2 178.2 0.59 0.38 0.92 
≤7 days, 10, 26W 43 136.6 93.0 200.7 0.63 0.39 1.02 
≤7 days HepB, 6, 10, 26W 43 170.6 114.6 254.1 0.78 0.48 1.28 
10, 14, 26W 41 392.6 323.3 476.7 1.80 1.24 2.60 
14, 26W, 9M 47 269.9 183.3 397.5 1.24 0.76 2.02 
GMC = geometric mean antibody concentration 
N = number of subjects with post-vaccination results available post-Dose 3; numbers will differ to ATP cohort for 
immunogenicity 
95% CI = 95% confidence interval  
*
See Figure 1 for study groups and vaccinations 
**
95% CI for the GMC ratio (Anova model - pooled variance) 
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Table 2 Safety outcomes following 18 months’ surveillance  
  Number (%) infants reporting symptoms 
Study groups†  ≤7D, 10, 
14W 
N1 = 60 
≤7D, 10, 
26W 
N1 = 59 
6, 10, 
14W‡‡ 
N1 = 54 
6, 10, 
26W 
N1 = 57 
≤7D HepB, 6, 
10, 26W 
N1 = 57 
10, 14, 
26W 
N1 = 52 
14, 26W, 
9M 
N1 = 57 
Control 
N1 = 52 
Pooled neonatal 
RTS,S 
N2 = 
119 
HepB  
N2 = 120 
Solicited injection site symptoms during 7-day post-vaccination period†† 
Pain  RTS,S/AS01E All 2 (1.2) 4 (2.5) 8 (5.1) 4 (2.4) 2 (1.2) 1 (0.7) 0 - 5 (4.2) - 
 Grade 3‡ 0 0 0 0 0 0 0 - 0 - 
 Control All 7 (6.8) 2 (3.7) 7 (4.5) 11 (9.9) 3 (2.7) 4 (3.9) 1 (1.8) 12 (7.8) - 3 (2.5) 
 Grade 
3‡† 
0 0 1 (0.6) 0 0 0 0 0 - 0 
Redness  RTS,S/ 
AS01E 
All 2 (1.2) 4 (2.5) 7 (4.5) 5 (3.0) 2 (1.2) 1 (0.7) 0 - 5 (4.2) - 
 Grade 3‡ 0 0 0 0 0 0 0 - 0 - 
 Control All 6 (5.8) 1 (1.9) 6 (3.8) 5 (4.5) 5 (4.4) 4 (3.9) 2 (3.5) 10 (6.5) - 7 (5.9) 
 Grade 3‡ 0 0 0 0 0 0 0 0 - 0 
Swelling  RTS,S/AS01E All 5 (3.1) 4 (2.5) 8 (5.1) 5 (3.0) 3 (1.8) 1 (0.7) 0 - 5 (4.2) - 
 Grade 3‡ 0 0 0 0 0 0 0 - 0 - 
 Control All 10 (9.7) 1 (1.9) 9 (5.8) 12 
(10.8) 
8 (7.1) 6 (5.9) 2 (3.5) 12 (7.8) - 6 (5.0) 
 Grade 3‡ 0 0 0 0 0 0 0 0 - 0 
Solicited general symptoms during 7-day post-vaccination period 
Drowsiness  All 0 0 0 0 0 0 1 (0.6) 0 0 1 (0.8) 
  Grade 3‡ 0 0 0 0 0 0 0 0 0 0 
Irritability  All 7 (4.3) 3 (1.9) 10 (6.4) 2 (1.2) 3 (1.8) 5 (3.4) 5 (3.0) 5 (3.2) 1 (0.8) 0 
  Grade 3‡ 0 0 1 (0.6) 0 0 0 0 1 (0.6) 0 0 
Loss of appetite All 0 0 1 (0.6) 0 1 (0.6) 0 2 (1.2) 1 (0.6) 0 0 
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  Grade 3‡ 0 0 0 0 0 0 0 0 0 0 
Fever  ≥38.0°C 28 (17.2) 24 (14.8) 26 (16.7) 17 
(10.3) 
16 (9.6) 24 (16.3) 23 (13.6) 15 (9.7) 17 
(14.3) 
8 (6.7) 
  >39.0°C‡ 0 1 (0.6) 1 (0.6) 0 0 1 (0.7) 2 (1.2) 0 0 0 
Unsolicited (spontaneously reported) symptoms during 30-day post-vaccination period  
  All 36 (60.0) 35 (59.3) 28 (51.9) 29 
(50.9) 
35 (61.4) 36 (69.2) 47 (82.5) 31 
(59.6) 
26 
(21.8) 
33 
(27.5) 
  Grade 3‡ 1 (1.7) 0 1 (1.9) 1 (1.8) 2 (3.5) 2 (3.8) 1 (1.8) 0   
  Related 0 0 0 1 (1.8) 0 0 0 0   
   Number (%) infants reporting serious adverse events following all doses of study vaccine 
Study groups  ≤7D, 10, 
14W 
N2 = 60 
≤7D, 10, 
26W 
N2 = 59 
6, 10, 
14W 
N2 = 60 
6, 10, 
26W 
N2 = 60 
≤7D HepB, 6, 
10, 26W 
N2 = 60 
10, 14, 
26W 
N2 = 60 
14, 26W, 
9M 
N2 = 60 
Control 
N2 = 60 
≤7D 
RTS 
N2 = 
119 
≤7D 
HepB 
N2 = 120 
SAEs (Month 0-18) All 7 (11.7) 5 (8.5) 6 (10.0) 9 (15.0) 8 (13.3) 12 (20.0) 5 (8.3) 4 (6.7) 2 (1.7) 3 (2.5) 
N
1
 = Number of subjects receiving 3 doses of RTS,S/AS01E or DTPw-HepB/Hib alone for control; analyses of 
safety following 3 doses of RTS,S/AS01E or DTPw-HepB/Hib alone enabled comparison of equal follow up and 
number of vaccination visits (age at vaccination and number of doses of RTS,S/AS01E co-administered with DTPw-
HepB/Hib differed) 
N
2
 = Total Vaccinated Cohort  
Pooled neonatal RTS,S groups (≤7 days, 10, 14 weeks and ≤7 days, 10, 26 weeks groups) 
Pooled neonatal HepB vaccine groups (HepB vaccine at ≤7 days, RTS,S/AS01E at 6, 10 and 26 weeks and Control 
[HepB vaccine at ≤7 days] groups) 
†
See Figure 1 for study groups and vaccinations 
††
All solicited injection site symptoms were considered related to vaccination 
‡
Grade 3 AEs were defined as: pain - cries when limb is moved/spontaneously painful; redness/ swelling - diameter 
>20 mm; drowsiness/ irritability/ unsolicited AEs - events preventing normal activity; loss of appetite- not eating at 
all; fever - temperature >39°C  
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‡‡
Standard 6,10,14 week reference schedule  
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Figure 1 Study design overview: study groups, vaccinations 
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Figure 2 CONSORT diagram for study participants 
   653 SCREENED  Screening failures: 
157 Inclusion/exclusion criteria  
 11 CW not due to an AE 
 3 Delayed lab results 
 1 LFU 
 1 Unavailability of internet randomisation system (SBIR) 
    
 
    
   480 ENROLLED 
                
≤7D, 10, 14W 
60 
≤7D, 10, 26W 
60 
6, 10, 14W 
60 
6, 10, 26W 
60 
≤7D HepB, 6, 10 ,26W 
60 
10, 14, 26W 
60 
14, 26W, 9M  
60 
Control 
60 
                
479 RTS,S/AS01E Dose 1 (Total Vaccinated Cohort) 
                
60 59 60 60 60 60 60 60 
Reasons for elimination: 
  1 subject number allocated 
but no dose given 
            
                
412 RTS,S/AS01E 3 doses Control 3 doses  
                
51 49 51 54 54 47 55 51 
Reasons for not receiving 3 doses: 
3 CW; 3 LFU; 3 Other 2 CW; 7 LFU; 2 Other 1 CW; 6 LFU; 2 Other 1 CW; 4 LFU; 1 Other 2 CW; 4 LFU 5 CW; 6 LFU; 1 AE; 1 SAE 3 LFU; 2 Other 2 CW; 6 LFU; 1 Other 
                
391 COMPLETED MONTH 18 VISIT 
                
46 46 48 52 50 44 53 52 
Reasons for withdrawal: 
6 CW; 8 LFU 3 CW; 10 LFU 1 Death; 3 CW; 8 LFU 
1 Death; 1 PV; 
1 CW; 5 LFU 
3 CW; 7 LFU 
1 Death; 5 CW; 
9 LFU; 1 AE 
1 CW; 6 LFU 2 CW; 6 LFU 
                
382 ATP IMMUNOGENICITY COHORT 
                
48 46 47 48 47 44 54 48 
Reasons for elimination: 
12 Vaccination schedule 
12 Vaccination schedule 
1 Concomitant vaccination 
12 Vaccination schedule 
1 Concomitant vaccination 
10 Vaccination schedule 
2 Concomitant vaccination 
13 Vaccination schedule 16 Vaccination schedule 6 Vaccination schedule 12 Vaccination schedule 
 
AC
CE
PT
ED
Copyright © 2018 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.
 35 
 
Figure 3 GMCs for anti-CS antibody concentration at each time point by group (ATP cohort for immunogenicity)  
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Figure 4 Bar graphs of solicited local and general symptoms reported during the 7-day (Days 0-6) 
post vaccination period following a neonatal dose of RTS,S/AS01E or a hepatitis B vaccine; pooled 
neonatal groups (Total Vaccinated Cohort) 
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